

Medicaid Long Acting Injectable Antipsychotic Coding Update

Neighborhood News – October 2025

Neighborhood Health Plan of Rhode Island (Neighborhood) is notifying providers that a configuration update has been implemented to **bypass prior authorization requirements** when a **long-acting injectable (LAI) antipsychotic** is processed at the pharmacy with an appropriate diagnosis of **schizophrenia or schizoaffective disorder**.

To ensure smooth claims processing, providers prescribing LAI antipsychotics for members with these diagnoses, should **include the appropriate diagnosis code on the prescription**.

This update is intended to **reduce administrative burden** by eliminating the need to submit prior authorization requests for these prescriptions.

In Scope Medications:

- Paliperidone palmitate extended-release injectable products
- Risperidone extended-release injectable
- Aripiprazole extended-release injectable products

In Scope Diagnoses/ICD-10 Codes:

- Schizophrenia: F20.0, F20.1, F20.2, F20.3, F20.5, F20.8, F20.81, F20.89, F20.9
- Schizoaffective Disorder: F25.0, F25.1, F25.8, F25.9

Please note these updates impact the Medicaid line of business only.

For a complete list of formulary drug therapies and prior authorization criteria, please visit [our pharmacy page](#).